Beam Therapeutics Inc
NASDAQ:BEAM 3:59:51 PM EDT
| Market Cap (Intraday) | 6.32B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $102.71 |
| 50-Day MA | $100.25 |
| 200-Day MA | $90.41 |
Beam Therapeutics Inc Stock, NASDAQ:BEAM
26 Landsdowne Street, 2nd floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.327.8775
Number of Employees: 181
Description
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.